M[embrane]{.smallcaps}-bound calnexin and its soluble homologue calreticulin behave in mammalian cells as authentic chaperones of the ER. They bind monoglucosylated high mannose-type oligosaccharides present in both misfolded and properly folded glycoproteins ([@B28]; [@B38]). Monoglucosylated structures may be formed by partial deglucosylation of the oligosaccharide transferred to nascent polypeptide chains (Glc~3~Man~9~GlcNAc~2~) by glucosidases I (GI)^1^ and II (GII) or by reglucosylation of Man~7-9~GlcNAc~2~ by the UDP-Glc:glycoprotein glucosyltransferase (GT) ([@B32]). GT behaves as a sensor of glycoprotein conformation since the glucose units removed from the monoglucosylated species by GII are added back by GT only when glycoproteins have not yet acquired their proper tertiary structures.

Binding of calnexin and calreticulin to monoglucosylated oligosaccharides of misfolded glycoproteins prevents their aggregation and premature degradation, inhibits formation of non-native disulfide bridges and retains misfolded species in the ER. The role of calnexin and calreticulin is therefore similar to that of classical chaperones of the Hsp70 and chaperonin families (see [@B12], and references therein).

The yeast *Schizosaccharomyces pombe* has the three elements required for the quality control of glycoprotein folding. This fission yeast has a calnexin-like molecule with a 40% amino acid identity with the mammalian lectin ([@B17]; [@B22]). The *S*. *pombe* calnexin is a transmembrane type I protein with a cytosolic tail and three highly conserved and one less conserved Ca^2+^-binding motifs, as in mammalian calnexin. Calnexin is essential for *S*. *pombe* viability and no calreticulin homologue was detected in this yeast genome ([@B17]; [@B22]). Moreover, it has been shown that conditions that lead to the accumulation of misfolded glycoproteins in the ER induce calnexin-encoding mRNA synthesis ([@B17]; [@B22]).

The oligosaccharide transferred to protein in *S*. *pombe* is Glc~3~Man~9~GlcNAc~2~, as in most eukaryotic cells. It is processed in the ER to Man~9~GlcNAc~2~, thus indicating the presence of both GI and GII activities although the genes encoding these glucosidases have not yet been identified ([@B39]).

We have previously characterized the *S*. *pombe* GT. The enzyme was purified to homogeneity and found to be even more stringent in its differential glucosylation of denatured and native glycoproteins than its rat liver counterpart ([@B6]). We showed that synthesis of *S*. *pombe* GT-encoding mRNA was induced under stress conditions that promoted accumulation of misfolded glycoproteins in the ER lumen ([@B5]). However, disruption of the GT-encoding gene showed that the enzyme is not essential for cell viability and no discernible phenotype was observed ([@B5]). On the other hand, the yeast *Saccharomyces cerevisiae* lacks GT, a key element in the quality control of glycoprotein folding, and calreticulin and its calnexin-like molecule presents significant structural variations with respect to the mammalian protein ([@B6]; [@B23] *b*; [@B16]).

Facilitation of glycoprotein folding mediated by the interaction of calnexin/calreticulin with monoglucosylated oligosaccharides is dispensable for cell growth as shown by the viability of *S*. *pombe* mutant cells lacking GII (our unpublished results), the same as mammalian cells lacking the same enzyme ([@B26]). No monoglucosylated oligosaccharides are formed in GII-deficient mutants. Facilitation of glycoprotein folding mediated by the ER lectins was therefore considered to be a back up system that the unique plasticity of the ER folding machinery could replace with alternative mechanisms.

Work reported here shows that: (*a*) facilitation of glycoprotein folding mediated by the interaction of calnexin and monoglucosylated oligosaccharides is essential for *S*. *pombe* viability under conditions of extreme ER stress such as glycoprotein underglycosylation and high temperature; (*b*) cycles of reglucosylation--deglucosylation catalyzed by GT and GII are apparently not essential for facilitation of glycoprotein folding; and (*c*) the formation of monoglucosylated oligosaccharides is not essential for *S*. *pombe* viability, thus indicating that calnexin has another essential role, independent of its recognition of monoglucosylated oligosaccharides. In addition, we have identified two amino acid residues that are apparently required for GT catalytic activity.

Materials and Methods {#MaterialsMethods}
=====================

Strains and Media
-----------------

The wild-type *S*. *pombe* strains used were Sp95 (h^90^, *ura4*-D18, *ade6*-M216, *leu1*-32) and Sp61 (h^−^, *ura4*-D18, *ade6*-M210, *ade1*, *leu1*-32). YE and minimal media were prepared as described ([@B20]).

Construction of the alg6 Mutant
-------------------------------

Degenerate oligonucleotide primers encoding three peptides that are conserved in known *ALG6* sequences from other species (these sequence data are available from GenBank/EMBL/DDBJ under accession Nos. [Z74910](Z74910) and [Z54342](Z54342)) were used as primers in PCR reactions: 5′-TAYTGGGGNTYNGAYTATCCNCC-3′ (Alg1′, sense), 5′-DATNGTYTTYTCRTGNACNYGRA-3′ (Alg4′, antisense), and 5′-CAYTGGATGGARATHAC-3′ (Alg6s, sense). The template was genomic *S*. *pombe* DNA. PCR reactions using primers Alg1′ and Alg4′ yielded an 812-bp fragment that was sequenced. The deduced amino acid sequence of this product was 82% and 80% homologous to the respective portions of *S*. *cerevisiae ALG6* and putative *Caenorhabditis elegans ALG6* gene products, respectively. An 876-bp fragment was obtained when primers Alg6s and Alg4′ were used. As expected, it contained the 812-bp fragment. The 812-bp fragment in pGEMT-Easy vector (Promega Corp., Madison, WI) was treated with BglII and NheI enzymes. A 102-bp segment was thus eliminated and replaced by the *ura4* ^+^ gene (these sequence data are available from GenBank/EMBL/DDBJ under accession No. [M36504](M36504); 1.8 kb) in an inverted position. The construct was liberated from the vector and used for transforming Sp95 cells. Ura4^+^ cells (*alg6*; Sp95A strain) were selected. Colony PCRs were performed using Alg6s (sense) and uraSC (sense, 5′-TGCTCCTACAACATTACC-3′; this primer is complementary to a portion of the 3′ end of the *ura4* ^+^ gene). Selected colonies gave the expected 423-bp fragment. DNAs from wild-type (Sp95) and *alg6* mutant cells were digested with BglII and NdeI (that do not cut the *ura4* ^+^ gene) and analyzed by Southern blotting. A 603-bp fragment obtained by digestion of the 812-bp portion of the *alg6* ^+^ gene with NheI and SphI was used as probe. Mutant and wild-type DNAs yielded 4.6-kb and 2.8-kb positive fragments, respectively. On the other hand, the mutant DNA 4.6-kb fragment gave a positive signal when a *ura4* ^+^-derived probe was used.

Construction of the gpt1/alg6 Double Mutant
-------------------------------------------

### Construction of the gpt1 Mutant.

The procedure used was similar to that previously described but Sp61 cells were used ([@B5]). The resulting strain was named Sp61G.

### Excision of the ura4^+^ Gene.

The pBluescript plasmid containing the entire *gpt1* ^+^ gene (4,952 bp) ([@B5]) was digested with BglII, thus eliminating 1,684 bp. The digestion product, containing the plasmid plus 612 bp of the 5′ end and 2,656 bp of the 3′ end of GT, was ligated. A 3,111-bp linear fragment obtained upon cutting the plasmid with PstI and MluI was used to transform *gpt1* mutant cells. Colonies resistant to fluororotic acid (1 mg/ml) were analyzed by Southern blotting (see below). The strain was named Sp61G4.

### Disruption of the alg6^+^ Gene.

The *alg6* ^+^ gene was disrupted in the *gpt1-* D1684 mutant (Sp61G4 strain), as described above for wild-type cells. The resulting strain was named Sp61G4A.

Characterization of gpt1 and gpt1/alg6 Mutants
----------------------------------------------

DNAs from wild-type cells (Sp61), and from the *gpt1::ura4* ^+^ (Sp61G), the *gpt1-*D1684 (Sp61G4) and the *gpt1/alg6* (Sp61G4A) mutant cells were cut with BglII and analyzed in Southern blots with a 1,200-bp probe corresponding to the 5′ end of the *gpt1* ^+^ gene. Wild-type DNA yielded two positive bands as BglII cuts at 612, 1,750, and 2,290 bp from the 5′ end of the *gpt1* ^+^ gene whereas *gpt1::ura4* ^+^, *gpt1*-D1684, and *gpt1/alg6* DNAs only showed a positive signal with the smaller band as 1,684 bp (from 612 to 2,296) from the *gpt1* ^+^ gene had been deleted for inserting the *ura4* ^+^ gene (*gpt1* mutant) or for constructing the *gpt1*-D1684 mutant. Wild-type DNA gave a 2.8-kb positive signal, the same as *gpt1::ura4* ^+^ and *gpt1-*D1684 DNAs when the above mentioned 603-bp *alg6* ^+^ gene probe was used. On the other hand, *gpt1/alg6* DNA gave the expected 4.6-kb band.

Construction of the gls2/alg6 Double Mutant
-------------------------------------------

### Disruption of the GII-encoding gene (gls2^+^).

Primers (sense 5*′*-TGGAAYGAYATGAAYGARCC-3*′*, and antisense 5*′*-IGCRTGNGCICKRAARAA-3*′*) were designed according to peptides conserved in three known GII sequences from other species (these sequence data are available from GenBank/EMBL/DDBJ under accession Nos. [Z36098](Z36098), [D42041](D42041), and Z700753). A 414-bp fragment of the homologue *S. pombe* gene (here designated *gls2* ^+^) was obtained by PCR using genomic wild-type DNA as template. The fragment was sequenced and an antisense primer (5*′*-CCACCGAACAAACAATTCAGC-3*′*) was designed corresponding to the sequence of positions 355--375 of the fragment. This primer and a sense primer derived from another sequence conserved among the three GIIs of other species (5*′*-AAYGCNGCNGANACNTGG-3*′*) were used to synthesize a 998-bp fragment by PCR. This fragment was cloned in the pGEMT-Easy vector (Promega Corp.) and sequenced. The deduced amino acid sequence of this fragment showed 49%, 43%, and 47% homologies with the corresponding respective fragments of human, *S. cerevisiae* and putative *C. elegans* GII sequences. The *ura4* ^+^ marker gene was introduced in reverse orientation in position 569 (HindIII site) of the 998-bp fragment. Wild-type cells (Sp95) were transformed with the linear 2,766-bp NotI restriction DNA fragment (Sp95IIα strain).

### Excision of the ura4^+^ Gene.

The vector containing the 998-bp fragment of *gls2* ^+^ with the inserted *ura4* ^+^ marker was treated with Bsu36I. A 4,565-bp fragment containing the vector plus 359 bp of the 5′ end of *gls2* ^+^, 776 bp of the 5′ end of the *ura4* ^+^, and 430 bp of the 3′ end of *gls2* ^+^ genes was ligated. A 1,565-bp linear fragment was liberated from it by NotI digestion and used for transforming the *gls2::ura4* ^+^ (Sp95IIα strain) mutant. Fluororotic acid (1 mg/ml) resistant colonies were characterized by PCR. Primers used were 5′-GTCGTCCGCTTCTCCCTC-3′ (GIIBs) and 5′-CCCCATAATGAATAGCAT-3′ (GIIBa). The primers are complementary to portions of the *gls2* ^+^ gene fragment. PCR generated a 542-bp fragment in wild-type cells, a 2,306-bp fragment in *gls2::ura4* ^+^ (Sp95IIα) cells, and a 1,108-bp fragment in *gls2::ura4* (Sp95IIα2) cells.

### Disruption of the alg6^+^ Gene.

*Gls2::ura4* (Sp95IIα2) cells were then transformed with the linear fragment mentioned before having portions of the *alg6* ^+^ gene interrupted with *ura4* ^+^ (see above, construction of the *alg6* mutant). Ura^+^ cells (*gls2/alg6*; Sp95IIα2A strain) were selected. Colony PCRs were performed using primers GIIBs and GIIBa or Alg6s and uraSC. Selected colonies gave the expected fragments of 1,108 bp with GIIBs and GIIBa primers and of 423 bp with the Alg6s and uraSC ones. It is worth mentioning that primer Alg6s was not present in the construct used for disrupting the *alg6* ^+^ gene but was complementary to a portion of the gene located to the 5′ end.

Mutagenesis of gpt1^+^
----------------------

The *gpt1* ^+^ gene was removed from the pBluescript plasmid and ligated to pALTER1 (Promega Corp.). Mutagenesis reactions were carried out as described by the manufacturer (pAlter kit; Promega Corp.). The primers used were Ampicillin repair, Tetracycline knockout, CTTACGTGGATTAAAAGCTCACATTAGTGCATTATATG for the Y1312A mutation and CCCTGTCTAATTTAGCTCAAGATTTGCCAAATC for the D1352A mutation. Amp^R^ and Tet^S^ cells were selected. Plasmid DNA (pALTER1-*gpt1^YD-AA^*) was isolated from those cells and the presence of new AluI sites in the *gpt1* gene was assayed. The mutations introduced are expected to create two new sites. As the *gpt1* ^+^ gene has 25 AluI sites, a 1,236-bp fragment of the COOH-terminal portion that contained the putatively mutated region was synthesized by PCR. The fragment coming from *gpt1* ^+^ yielded, as expected, five fragments upon digestion with AluI, whereas seven fragments were obtained from that coming from the Y1312A, D1352A GT mutant (*gpt1^YD-AA^*). Similar results were obtained in all five independently PCR-synthesized 1,236-bp fragments.

Subcloning of gpt1^YD-AA^ in pREP1
----------------------------------

pALTER1-*gpt1^YD-AA^*was digested with SphI, treated with T4 DNA polymerase for generating blunt ends, and then digested with BamHI. The *gpt1^YD-AA^* gene was isolated and ligated to the pREP1 expression vector (this vector contains the *LEU2 S*. *cerevisiae* gene that complements the *leu1 S*. *pombe* mutation) that had been cut with SmaI and BamHI. Resulting plasmid was called pREP1-*gpt1^YD-AA^*. *S*. *pombe gpt1/alg6* cells were transformed with this construct and plated in minimal medium supplemented with adenine.

Subcloning of gpt1^+^ in pREP1 and pREP41
-----------------------------------------

The *gpt1* ^+^ gene was isolated from the pBluescript as described above and ligated to pREP1 or pREP41. Resulting expression vectors were called pREP1-*gpt1* ^+^ or pREP41*-gpt1* ^+^. *Gpt1* or *gpt1/alg6* cells were then transformed with these constructs and plated in minimal medium supplemented with adenine.

DNA and RNA procedures
----------------------

Standard DNA manipulations were carried out as described ([@B29]). *S*. *pombe* genomic DNA was prepared as previously described (Moreno et al., 1989). Hybridization conditions were as previously described ([@B29]). RNA was extracted from cells grown under normal conditions (YE medium at 28°C) in the exponential growth phase at the same OD and submitted to Northern blotting as previously performed ([@B5]). The probe used was a 1,004-bp DNA fragment of the BiP-encoding gene synthesized by PCR using genomic DNA as template.

Materials
---------

\[^14^C\]Glucose (250 Ci/mol) and EasyTag Express protein labeling mix (\>1,000 Ci/mmol) were from New England Nuclear (Boston, MA). Jack bean α-mannosidase and EndoH were from Sigma (St. Louis, MO). UDP- \[^14^C\]Glc (250 Ci/mol) was prepared as described by [@B37]. Polyclonal antiserum to recombinant *S*. *pombe* calnexin was a generous gift from Dr. L. Rokeach (Département de Biochimie, Université de Montréal, Montréal, Canada).

Substrates and Standards
------------------------

\[*glucose*-^14^C\]Glc~1~Man~9~GlcNAc, \[*glucose*-^14^C\]Glc~3~Man~9~GlcNAc, \[*glucose*- ^14^C\]Glc~2~Man~9~GlcNAc, \[*glucose*-^14^C\]Glc~1~Man~4~GlcNAc, \[*glucose*-^14^C\]Glc~1~Man~5~GlcNAc, \[^14^C\]ManGlcNAc, \[^14^C\]Man~9~GlcNAc, and \[^14^C\]Man~8~GlcNAc were prepared as described previously ([@B6]).

In Vivo Labeling of  S. pombe Cells with \[^14^C\]glucose
---------------------------------------------------------

Pulse labeling of *S*. *pombe* wild type, *alg6*, *gpt1/alg6*, and *gls2/alg6* cells with \[^14^C\]glucose was performed as described before for *S*. *cerevisiae* but 150 μCi of \[^14^C\]glucose was used ([@B6]). Preincubations and incubations with the labeled precursor lasted for 15 min. Where indicated 5 mM 1-deoxynojirimycin (DNJ) was added. Isolation of Endo H--sensitive oligosaccharides was performed as already described ([@B6]).

In Vivo Labeling of  S. pombe Cells with \[^35^S\]Methionine and \[^35^S\]Cysteine
----------------------------------------------------------------------------------

Wild type (Sp95), *gls2*, and *alg6* mutant cells grown in YE medium were harvested, washed, and then suspended (2 × 10^8^ cells) in 1.5 ml of 1% Yeast Nitrogen Base without amino acids (Difco Laboratories Inc., Detroit, MI) supplemented with adenine, leucine, and uracil. Samples were preincubated for 2 h at 28°C and incubated with 450 μCi of \[^35^S\]methionine plus \[^35^S\]cysteine (EasyTag Express protein labeling mix) for 5 min at the same temperature. Reactions were stopped by the addition of 10 mM sodium azide plus 10 mM iodoacetamide. Samples were then processed and calnexin was immunoprecipitated as described previously ([@B33]). Samples were run on 9% SDS-PAGE and submitted to autoradiography.

Methods
-------

Strong acid hydrolysis and treatment of oligosaccharides with Jack bean α-mannosidase were as described before ([@B6]). Whatman 1 paper was used for chromatography. Solvents used were: (*a*) 1-propanol/nitromethane/water (5:2:4); (*b*) 1-butanol/pyridine/water (10:3:3); or (*c*) 1-butanol/pyridine/water (4:3:4). GII activity was assayed as described before using \[*glucose-* ^14^C\]Glc~1~Man~9~GlcNAc as substrate ([@B35]). GT was assayed using yeast cell microsomes as an enzyme source and 8 M urea-denatured thyroglobulin as acceptor, as described previously ([@B34]). *S*. *pombe* and rat liver microsomes were prepared as already described (Trombetta et al., 1992; [@B6]). Endomannosidase was assayed in *S*. *pombe* microsomes with \[*glucose*-^14^C\]Glc~1~Man~9~GlcNAc as substrate as already described ([@B7]). Rat liver microsomes with or without *S*. *pombe* microsomes were used as positive controls.

Results {#Results}
=======

Glycosylation and Oligosaccharide-processing Pathways
-----------------------------------------------------

The glycosylation and oligosaccharide processing pathways occurring in the ER of wild type and mutant cells used in the work reported here are depicted in Fig. [1](#F1){ref-type="fig"}. *Gpt1* ^+^, *gls2* ^+^, and *alg6* ^+^ code for GT, for GII and for the enzyme that transfers the first glucose unit from dolichol-P-Glc to Man~9~GlcNAc~2~-P-P-dolichol, respectively. Mutants were obtained and genetically characterized by Southern blotting and PCR analysis as described under Materials and Methods (Table [I](#TI){ref-type="table"}).

Biochemical Characterization of Mutants
---------------------------------------

### The alg6 Mutation.

The *gpt1* ^+^ gene encoding *S*. *pombe* GT has already been identified but as neither *alg6* ^+^ nor *gls2* ^+^genes have yet been identified in *S*. *pombe*, it was necessary to characterize the *alg6*, *gpt1/alg6*, and *gls2/alg6* mutants biochemically. For this purpose, the structure of protein-bound oligosaccharides synthesized in vivo by the wild-type and mutant cells in the presence or absence of the GI and GII inhibitor DNJ were compared. Incubation of wild-type cells with \[^14^C\]glucose for 15 min in the presence 5 mM DNJ yielded endo-β-*N*-acetylglucosaminidase H (Endo H)-sensitive, protein-linked oligosaccharides that migrated on paper chromatography as Glc~3~Man~9~GlcNAc, Glc~2~Man~9~GlcNAc, and Glc~1~Man~9~GlcNAc standards (Fig. [2](#F2){ref-type="fig"} *A*). Strong acid hydrolysis of compounds that migrated as either one of the last two standards produced labeled glucose and mannose units (Fig. [3](#F3){ref-type="fig"} *A*). Omission of DNJ mainly produced compounds that migrated as Man~9~GlcNAc and Man~8~GlcNAc standards but a trailing in the position of Glc~1~Man~9~GlcNAc could be observed (Fig. [2](#F2){ref-type="fig"} *B*). Strong acid hydrolysis of compounds in this figure yielded mannose and very small amounts of glucose and galactose (Fig. [3](#F3){ref-type="fig"} *B*). From these results it is concluded that DNJ only partially inhibited GI and GII activities.

The *alg6* mutant cells incubated in the presence of DNJ mainly produced compounds that migrated as Glc~1~Man~9~GlcNAc, Man~9~GlcNAc, and Man~8~GlcNAc standards (Fig. [2](#F2){ref-type="fig"} *C*). Treatment of compounds that migrated as the first two standards with Jack bean α-mannosidase yielded mannose, ManGlcNAc, and compounds that migrated as Glc~1~Man~4~GlcNAc and Glc~1~Man~5~GlcNAc standards (Fig. [3](#F3){ref-type="fig"} *C*). Strong acid hydrolysis of these last two compounds produced labeled glucose and mannose units (Fig. [3](#F3){ref-type="fig"} *D*). The α-mannosidase degradation products confirmed that a mixture of Man~9~GlcNAc and Glc~1~Man~9~GlcNAc was present in the main peak of Fig. [2](#F2){ref-type="fig"} *C*. ManGlcNAc was produced upon degradation of the first compound and Glc~1~Man~4,5~GlcNAc by that of the last one. Labeling of the mutant performed in the absence of DNJ only yielded Man~9~GlcNAc and Man~8~GlcNAc (Fig. [2](#F2){ref-type="fig"} *D*). Strong acid hydrolysis of those compounds only produced mannose units (Fig. [3](#F3){ref-type="fig"} *E*).

As only partial inhibition of GII by DNJ was attained, there are two interpretations to results shown above: in *alg6* mutants, Man~9~GlcNAc~2~ was transferred to proteins and this compound was either demannosylated to Man~8~GlcNAc~2~ or glucosylated by GT to Glc~1~Man~9~GlcNAc~2~ or alternatively, the disrupted gene (*alg6* ^+^) corresponds to the enzyme that transfers not the first but the second glucosyl residue to Man~9~GlcNAc~2~-P-P-dolichol. According to this interpretation, Glc~1~Man~9~GlcNAc~2~was transferred in the mutant obtained and this compound was deglucosylated and demannosylated to Man~9~GlcNAc~2~ and Man~8~GlcNAc~2~. Characterization of the *gpt1/alg6* double mutant discarded this last possibility.

### The gpt1/alg6 Double Mutation.

Incubation of *gpt1/alg6* cells with \[^14^C\]glucose yielded protein-linked Man~9~GlcNAc and Man~8~GlcNAc both in the presence and absence of DNJ (Fig. [4](#F4){ref-type="fig"}, *A* and *B*). Strong acid hydrolysis of compounds obtained under both conditions only produced labeled mannose residues (Fig. [4](#F4){ref-type="fig"}, *C* and *D*). Furthermore, microsomes obtained from the double mutant were completely devoid of GT activity (not shown; the assay and results were as described before for the *gpt1* mutant; [@B5]). These results indicate that in *gpt1/alg6* double-mutant cells Man~9~GlcNAc~2~ was transferred to nascent polypeptide chains and that this compound was not glucosylated. They further indicate that the same compound was transferred in the single *alg6* mutant.

### The gls2/alg6 Double Mutation.

Incubation of *gls2/alg6* mutant cells with \[^14^C\]glucose in the absence of DNJ yielded a mixture of Glc~1~Man~9~GlcNAc~2~, Man~9~GlcNAc~2~, and Man~8~GlcNAc~2~ (Fig. [5](#F5){ref-type="fig"} *A*). The same result was obtained in the presence of the GII inhibitor (not shown). Strong acid degradation of above mentioned compounds yielded glucose and mannose (Fig. [5](#F5){ref-type="fig"} *B*). No GII activity was detected in *gls2/alg6* microsomes when assayed with \[*glucose*-^14^C\]Glc~1~Man~9~GlcNAc as substrate.

Presence of the Unfolded Protein Response in alg6, gpt1/alg6, and gls2/alg6 Mutants
-----------------------------------------------------------------------------------

Accumulation of misfolded proteins in the ER leads to the so-called unfolded protein response, that is, to the induction of chaperones and other proteins that facilitate protein folding (BiP, calnexin, GT, etc.) ([@B25]; [@B17]; [@B22]; [@B5]). Detection of this response is rather simple in *S*. *pombe* as under normal conditions a single BiP-encoding mRNA is synthesized. Accumulation of misfolded proteins leads to the induction of not only this mRNA species but also of a slightly smaller mRNA (Pidoux and Amstrong, 1992). Synthesis of both BiP-encoding mRNAs was detected in *alg6*, *gpt1/alg6*, and *gls2/alg6* mutants but not in wild-type cells grown under normal conditions (Fig. [6](#F6){ref-type="fig"} *A*). The most plausible explanation for induction of BiP-encoding mRNA in cells carrying the *alg6* mutation might be that underglycosylation of glycoproteins occurs in them as has been described for *S*. *cerevisiae* mutants transferring Man~9~GlcNAc~2~to proteins ([@B1]). Cell-free assays have shown that in most eukaryotic cells Glc~3~Man~9~GlcNAc~2~ is transferred ∼10--25-fold more efficiently than Man~9~GlcNAc~2~ ([@B2]). It has been reported that underglycosylation of glycoproteins triggers misfolding of glycoproteins ([@B19]; [@B14]). To confirm that underglucosylation of glycoproteins occurred in *S*. *pombe* mutants carrying the *alg6* mutation, wild-type, *gls2*, and *alg6* cells were incubated for 5 min with a mixture of \[^35^S\]methionine and \[^35^S\]cysteine, lysed in the presence of iodoacetamide and material immunoprecipitated by a calnexin antiserum run on SDS-PAGE under reducing conditions. As depicted in Fig. [6](#F6){ref-type="fig"} *B*, whereas a single positive band appeared in wild-type cells, two positive signals were detected in the *alg6* mutant. Their difference in size was of ∼2 kD, a value consistent with the presence of a single oligosaccharide in *S*. *pombe* calnexin ([@B17]; [@B22]). The *gls2* mutant yielded a single positive signal that migrated slightly above that of wild-type cells. This result is consistent with the fact that in this mutant the oligosaccharide retains two glucose units.

Growth and Morphology of Wild Type, alg6, gpt1, and gpt1/alg6 cells at 28° and 37°C
-----------------------------------------------------------------------------------

*Alg6* and *gpt1* cells grew at about the same rate as wild-type cells at 28°C (Fig. [7](#F7){ref-type="fig"} *A*). Moreover, their short rod shapes were similar to those of wild-type cells (Fig. [8](#F8){ref-type="fig"}, *A--C*). On the other hand, *gpt1/alg6* cells grew much more slowly than wild-type cells and growth stopped at a lower OD (Fig. [7](#F7){ref-type="fig"} *A*). *Gpt1/alg6* cells tended to clump and had a rounded shape with clearly visible inclusions (Fig. [8](#F8){ref-type="fig"} *D*). All mutant cells grew at 37°C except for *gpt1/alg6* that did not grow at this temperature (Fig. [9](#F9){ref-type="fig"}). Growth of *gpt1* mutant cells at the high temperature was similar to that of wild-type cells, whereas *alg6* cells grew somewhat less efficiently (Fig. [9](#F9){ref-type="fig"}). It is worth mentioning in experiments shown in Fig. [9](#F9){ref-type="fig"} all strains were allowed to grow for 5 d except for *gls2/alg6* and *gpt1/alg6* that were incubated for 7 and 10 d, respectively. Both *alg6* and *gls2/alg6* mutants showed the so-called thermosensitive morphology at 37°C, characterized by swollen cells, displaying pear, lemon, and round shapes ([@B15]).

Rescue of the Wild-Type Phenotype in gpt1/alg6 Mutants
------------------------------------------------------

The rounded shape of *gpt1/alg6* cells suggested that synthesis of one of the components of the cell wall was affected. A classical way to test this hypothesis is to grow cells in a hyperosmotic medium. As shown in Fig. [10](#F10){ref-type="fig"} *A*, *gpt1/alg6* cells recovered the wild-type morphology when grown in 1 M sorbitol. Double-mutant cells grew at 28°C at the same rate as wild-type ones in the presence of the above mentioned compound (not shown). To confirm that the phenotype observed in those double mutants was caused by the absence of GT, cells were transfected with two expression vectors, pREP1-*gpt1* ^+^ and pREP41-*gpt1* ^+^ both coding for GT. They respectively had strong and medium promoters and when transfected into *gpt1* mutants they yielded cells displaying 4--10- and 1--2-fold the GT activity of wild-type cells. *Gpt1/alg6* cells recovered the wild-type morphology (Fig. [10](#F10){ref-type="fig"} *B*) and growth rate at 28°C (Fig. [7](#F7){ref-type="fig"} *B*), and the ability to grow at 37°C (Fig. [9](#F9){ref-type="fig"}) when transfected with any of these expression vectors. The wild-type phenotype was not rescued by the vectors lacking the *gpt1* ^+^ gene (Fig. [10](#F10){ref-type="fig"} *C*).

It was reported that under physiological conditions of pH and salt concentration, GT interacted with hydrophobic peptides and that this interaction was blocked by denatured glycoproteins. It was postulated that this interaction could be one of the recognition elements that determine the exclusive glucosylation of misfolded species ([@B31]). The in vivo interaction of GT with certain misfolded ER proteins under conditions of Ca^2+^ depletion has also been reported ([@B3]). To check if the rescue of the wild-type phenotype by the GT-expressing vectors was caused by the catalytic activity of the enzyme or by its capacity of binding hydrophobic domains, two point mutations were introduced at the COOH-terminal domain of GT. This domain is believed to harbor the catalytic activity as it is 68--70% identical among the four known GT sequences (*Drosophila melanogaster*, *S*. *pombe*, *C*. *elegans*, and rat liver) ([@B21]; [@B5]; these sequence data are available from GenBank/EMBL/DDBJ under accession No. [U28735](U28735); our unpublished results) and also has a limited but significant homology with bacterial glycosyltransferases that use UDP-Glc or UDP-Gal as sugar donor ([@B21]). The changes introduced were Y1312A and D1352A. Both amino acids are not only conserved in the above mentioned GTs but also in at least nine bacterial glycosyltransferases. The mutated GT in pREP1 (pREP1- *gpt1^YD-AA^*)was completely inactive when expressed in *gpt1/ alg6* cells (Table [II](#TII){ref-type="table"}). The double-mutant cells expressed similar amounts of GT when transfected with pREP1- *gpt1* ^+^ or with pREP1-*gpt1^YD-AA^* as judged by Coomassie brilliant blue staining of SDS-PAGE of the soluble content of microsomes. The high molecular weight of the enzyme and its absence in non-transformed cells eased its identification. The mutated enzyme did not revert the *gpt1/alg6* phenotype (Fig. [10](#F10){ref-type="fig"} *D*) and did not allow growth of the double mutant at 37°C (not shown). This result confirmed that the enzymatic activity of GT was responsible for the correction of the phenotype and strongly suggested that the correction observed was mediated by the interaction of monoglucosylated species with calnexin.

Growth and Morphology of gls2/alg6 Cells
----------------------------------------

*Gls2/alg6* cells grew at 28°C at almost the same rate as wild-type or *alg6* cells (not shown). Moreover, the double-mutant cells displayed the same morphology as wild-type or *alg6* cells when grown at 28°C (Fig. [11](#F11){ref-type="fig"}, *A* and *B*) and were able to grow at 37°C although not as efficiently as *alg6* mutants (Fig. [9](#F9){ref-type="fig"}). As mentioned above, both *alg6* and *gls2/alg6* mutant cells showed the so called thermosensitive morphology at 37°C, characterized by swollen cells, displaying pear, lemon, and round shapes ([@B15]). The fact that *gls2/alg6* cells exhibited a phenotype of growth and morphology clearly different from that of *gpt1/alg6* cells indicates that facilitation of glycoprotein folding mediated by the interaction of monoglucosylated oligosaccharides with calnexin does not necessarily require cycles of reglucosylation--deglucosylation catalyzed by the opposing activities of GT and GII.

Discussion {#Discussion}
==========

It has been reported that in wild-type *S*. *pombe* cells the Glc~3~Man~9~GlcNAc~2~ transferred is deglucosylated to Man~9~GlcNAc~2~ in the ER, and then elongated by the addition of mannose and galactose residues in the Golgi ([@B39]). However, we have always obtained small amounts of Man~8~GlcNAc~2~. This compound was presumably not produced in the Golgi but in the ER as it was detected after very short incubations with the labeled precursor (5 min) or after long incubations (90 min) under conditions that prevented almost completely (addition of 5 mM DTT to the incubation medium) or completely (incubation at 39°C) exit of glycoproteins from the ER. Man~8~GlcNAc~2~ was not formed by an endomannosidase activity similar to that described previously in other cell types ([@B18]), as we have been unable to detect such activity in *S*. *pombe* microsomal membranes (see Materials and Methods). A phylogenetic survey has indicated a late evolutionary appearance of the enzyme ([@B4]). Accordingly, no endomannosidase activity has been detected so far in unicellular organisms including protozoa and yeasts ([@B7]; [@B8]; [@B4]).

Labeling of intact mutant cells with \[^14^C\]glucose for 15 min provided further evidence against the possibility that Man~8~GlcNAc~2~ could had been formed by an endomannosidase activity. As depicted in Fig. [4](#F4){ref-type="fig"}, Man~8~GlcNAc~2~ was produced in *gpt1/alg6* mutant cells, in which no glucosylated oligosaccharides (the substrate for the endomannosidase) were synthesized. In addition, incubation of *gls2* mutant cells (Sp95IIα strain; see Table [I](#TI){ref-type="table"}) with \[^14^C\]glucose led to the formation of protein-bound Glc~2~Man~9~GlcNAc~2~ and Glc~2~Man~8~GlcNAc~2~. No glucose-free compounds were detected, thus indicating that removal of the glucose units was not required for formation of oligosaccharides containing eight mannose residues.

In contrast to what was observed in mammalian, plant and protozoan cells incubated with \[^14^C\]glucose (see [@B24] for references), Glc~1~Man~8~GlcNAc~2~ was not detected in any of the *S*. *pombe* wild-type or mutant cells used in this study (Glc~1~Man~8~GlcNAc would have migrated on paper chromatography between Man~9~GlcNAc and Man~8~GlcNAc). The absence of Glc~1~Man~8~GlcNAc~2~ formation suggests that the mannosidase responsible for Man~8~GlcNAc~2~ formation and GT might be located in different ER subcompartments. An alternative possibility is that the Man~8~GlcNAc~2~ isomer formed may lack the mannose unit to which the glucose residue is added by GT.

Glycoproteins synthesized in *S*. *pombe* mutants that transfer Man~9~GlcNAc~2~ to proteins (*alg6* mutants) were found to be underglycosylated. It is known that in cell-free assays the oligosaccharyltransferase transfers Glc~3~Man~9~GlcNAc~2~about 10--25-fold faster than Man~9~GlcNAc~2~ ([@B2]). Glycoproteins synthesized in *S*. *cerevisiae* mutants that transfer the last compound were also found to be underglycosylated ([@B1]). It is not surprising, therefore, that induction of BiP-encoding mRNA was detected in all *S*. *pombe* strains having the *alg6* mutation. The extreme plasticity of the ER folding machinery compensated folding problems caused by glycoprotein underglycosylation by increased synthesis of chaperones and other folding-assisting proteins (BiP, GT, calnexin, etc.) and no discernable phenotype could be observed in those mutants at 28°C.

Facilitation of glycoprotein folding mediated by the interaction between monoglucosylated oligosaccharides and calnexin prevented appearance of a discernable phenotype in *alg6* mutants because *gpt1/alg6* double-mutant cells, in which no monoglucosylated oligosaccharides were formed, grew very slowly and with an altered morphology at 28°C and were unable to grow at 37°C. A wild-type phenotype was restored upon transfection with a GT-encoding plasmid. Two amino acid changes in the proposed catalytic domain of GT that abolished its glucosylating activity resulted in the non restoration of the wild-type phenotype. This result confirmed that the interaction of monoglucosylated compounds created by GT with calnexin was responsible for the rescue of *gpt1/alg6* cells.

Single *gpt1* mutants grown under normal conditions also showed an induction of BiP-encoding mRNA (not shown). This fact, as well as the already known induction of GT-encoding mRNA in cells submitted to conditions that promote accumulation of misfolded proteins in the ER ([@B5]), confirmed the involvement of monoglucosylated oligosaccharides created by GT in facilitation of glycoprotein folding. Moreover, the fact that Glc~1~Man~9~GlcNAc~2~ could only be detected in *alg6* mutants when DNJ had been added to the medium or when the *gls2* ^+^ gene had been disrupted confirmed that *S*. *pombe* GT is involved, together with GII, in glucosylation--deglucosylation cycles, like its mammalian counterpart, and not in the synthesis of cellular polysaccharides. Single *gpt1* mutants did not show a discernable phenotype as in them no underglycosylation of glycoproteins is expected to occur and probably increased synthesis of BiP and other folding-assisting proteins compensate for the absence of glycoprotein reglucosylation.

As mentioned above, many glycoproteins are expected to have folding problems in *gpt1/alg6* mutant cells. However, not all glycoproteins are affected in the same manner as the requirement for the presence of all oligosaccharides for correct folding varies among different glycoproteins (see [@B11], and references therein). The one (or ones) that is responsible for the phenotype observed is probably somehow involved in cell wall formation as normal growth and morphology could be restored in a hyperosmotic medium (addition of 1 M sorbitol). It is worth mentioning that *S*. *pombe* mutant cells affected in the galactomannan content displayed a rounded morphology similar to that of *gpt1/alg6* cells ([@B27]). Moreover, the morphological alteration in those mutants was corrected when grown in 1 M sorbitol the same as with the double mutants described in the present report. Synthesis of galactomannan is initiated in the ER upon transfer of Glc~3~Man~9~GlcNAc~2~ to a protein core.

This is the first report showing that protein reglucosylation by GT is required for cell viability under conditions of extreme ER stress such as glycoprotein underglycosylation and high temperature.

It has been reported that proper folding was arrested upon preventing the dissociation of influenza hemagglutinin (a glycoprotein having seven *N*-linked oligosaccharides) with calnexin/calreticulin by the addition of glucosidase inhibitors to an in vitro translation system ([@B10]). It was concluded that on-and-off cycles of interaction between the glycoprotein and the lectins catalyzed by GT and GII were required for folding facilitation. This would be analogous to what happens with chaperones of the Hsp70 family. Mutations in the NH~2~-terminal portion that abolish the ATPase activity and thus delay dissociation of the chaperones and misfolded proteins, prevent proper folding ([@B13]). Apparently cycles of reglucosylation--deglucosylation are not essential for facilitation of proper folding of the glycoprotein(s) responsible for the observed phenotype in *gpt1/alg6* cells as *gls2/alg6* double-mutant cells that transferred Man~9~GlcNAc~2~ and were unable to remove the glucose units added by GT as they lacked GII, had a phenotype of growth and morphology very similar to that of wild-type cells at 28°C and were able to grow at 37°C. It has been reported that at least two oligosaccharides in RNase B were required to immunoprecipitate the glycoprotein with anticalnexin antibodies ([@B28]). This indicates that the affinity of calnexin for monoglucosylated oligosaccharides is not as high as those of classical plant lectins. This was confirmed by the fact that isolated monoglucosylated oligosaccharides could be washed out with buffer from an immobilized calnexin column ([@B36]). It may be speculated, therefore, that even in the absence of GII association--dissociation cycles of binding of calnexin with the glycoprotein(s) responsible for the altered phenotype of *gpt1/alg6* cells could occur if the glycoprotein had a single (or few) oligosaccharide.

As mentioned above, calnexin is essential for *S*. *pombe* viability ([@B17]; [@B22]). The fact that *gpt1/alg6* mutant cells grew, albeit at a slower rate, at 28°C indicates that calnexin has another role, besides that of binding monoglucosylated oligosaccharides in this yeast. The calnexin homologue in *S*. *cerevisiae* is not essential for survival, and although mammalian cells devoid of calnexin are viable it is unknown whether cells lacking both calnexin and calreticulin can survive ([@B23] *b*; [@B30]).

It is worth mentioning that *S*. *cerevisiae alg5* or *alg6* mutants are similar to the *gpt1/alg6* double mutant in *S*. *pombe* as Man~9~GlcNAc~2~ is transferred to proteins in them and there is no GT in *S*. *cerevisiae*. Nevertheless, no thermosensitive phenotype has been observed in *S*. *cerevisiae alg5* or *alg6* mutants ([@B16]).

Trypanosomatid protozoa are similar to *alg6* mutants in *S*. *pombe* as in them unglucosylated oligosaccharides are transferred to proteins and they have GT ([@B24]). However, in this case no underglycosylation of glycoproteins is expected to occur as the protozoan oligosaccharyltransferase transfers, in cell-free assays, Glc~1-3~Man~9~GlcNAc~2~ and Man~7-9~GlcNAc~2~ at the same rate ([@B2]). It may be speculated that the specificity of the oligosaccharyltransferase in these protozoa is an evolutionary consequence of the loss of the ability to form Glc~3~Man~9~GlcNAc~2~ to prevent underglycosylation of proteins and thus a potential source of stress.

This work has received financial support from the United States Public Health Service (Grant GM 44500), from the Howard Hughes Medical Institute (Grant 75197-553502), from the University of Buenos Aires, and from the National Research Council (Argentina).
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![Glycosylation and oligosaccharide processing pathways occurring in the ER of wild-type and mutant cells used in work reported here. *D*, dolichol; *Pr*, protein.](JCB9806006.f1){#F1}

###### 

S. pombe Strains Used in the Present Study

  Strain                       Genotype
  ------------------------- -- -----------------------------------------------------------------------------------
  Sp95 (wt)                    h^90^, *ura4*-D18, *ade6*-M216, *leu1*-32
  Sp61 (wt)                    h^−^, *ura4*-D18, *ade6*-M210, *ade1*, *leu1-*32
  Sp95A (*alg6*)               h^90^, *ura4*-D18, *ade6*-M216, *leu1*-32, *alg6::ura4* ^+^
  Sp61G (*gpt1*)               h^−^, *ura4*-D18, *ade6*-M210, *ade1*, *leu1-*32,  *gpt1::ura4* ^+^
  Sp61G4                       h^−^, *ura4*-D18, *ade6*-M210, *ade1*, *leu1-*32,  *gpt1*-D1684
  Sp61G4A (*gpt1/alg6*)        h^−^, *ura4*-D18, *ade6*-M210, *ade1*, *leu1-*32,  *gpt1*-D1684, *alg6::ura4* ^+^
  Sp95IIα (*gls2*)             h^90^, *ura4*-D18, *ade6*-M216, *leu1*-32, *gls2::ura4* ^+^
  Sp95IIα2                     h^90^, *ura4*-D18, *ade6*-M216, *leu1*-32, *gls2::ura4*
  Sp95IIα2A (*gls2/alg6*)      h^90^, *ura4*-D18, *ade6*-M216, *leu1*-32, *gls2::ura4*,  *alg6::ura4* ^+^

Except for the first wild-type strains, all mutants were generated in the present study.  

![Characterization of *alg6* mutant. Patterns of protein-linked oligosaccharides. Oligosaccharides synthesized in wild-type (Sp95) and *alg6* mutant cells incubated for 15 min with \[^14^C\]glucose in the presence or absence of DNJ were obtained by Endo H treatment and subjected to paper chromatography with solvent *A*. Standards: *1*, Glc~1~Man~9~GlcNAc; *2*, Glc~2~Man~9~GlcNAc; *3*, Glc~3~Man~9~GlcNAc; *4*, Man~9~GlcNAc; and *5*, Man~8~GlcNAc.](JCB9806006.f2){#F2}

![Characterization of the *alg6* mutant. Monosaccharide composition of oligosaccharides. (*A*) The compound migrating as the Glc~1~Man~9~GlcNAc standard in Fig. [2](#F2){ref-type="fig"} *A* was submitted to strong acid hydrolysis. (*B*) All compounds depicted in Fig. [2](#F2){ref-type="fig"} *B* were submitted to the same treatment. Resulting products in *A* and *B* were run on paper chromatography with solvent *B*. (*C*) Compounds depicted in Fig. [2](#F2){ref-type="fig"} *C* that migrated as Glc~1~Man~9~GlcNAc and Man~9~GlcNAc standards were treated with α-mannosidase and run on paper chromatography with solvent *C*. (*D*) Compounds migrating as Glc~1~Man~5~GlcNAc and Glc~1~Man~4~GlcNAc standards in *C* were submitted to strong acid hydrolysis. (*E*) All compounds depicted in Fig. [2](#F2){ref-type="fig"} *D* were submitted to strong acid hydrolysis. Resulting products in *D* and *E* were run on paper chromatography with solvent *B*. Standards: *1*, galactose; *2*, glucose; *3*, mannose; *4*, Glc~1~Man~5~GlcNAc; *5*, Glc~1~Man~4~GlcNAc; and *6*, ManGlcNAc.](JCB9806006.f3){#F3}

![Characterization of the *gpt1/alg6* mutant. Patterns of oligosaccharides and monosaccharide compositions. (*A* and *B*) oligosaccharides synthesized upon incubation of *gpt1/alg6* mutant cells with \[^14^C\]glucose, in the presence or absence of DNJ, were run on paper chromatography with solvent *A*. (*C* and *D*) Compounds synthesized in the presence or absence of DNJ were submitted to strong acid hydrolysis. Resulting products were run on paper chromatography with solvent *B*. Standards: *1*, Glc~1~Man~9~GlcNAc; *2*, Man~9~GlcNAc; *3*, Man~8~GlcNAc; *4*, galactose; *5*, glucose; and *6*, mannose.](JCB9806006.f4){#F4}

![Characterization of *gls2/alg6* mutant. Patterns of oligosaccharides and monosaccharide composition. (*A*) Oligosaccharides synthesized by *gls2/alg6* mutant cells upon incubation with \[^14^C\]glucose in the absence of DNJ were run on paper chromatography with solvent *A*. (*B*) Compounds synthesized were submitted to strong acid hydrolysis and resulting products run on paper chromatography with solvent *B*. Standards: *1*, Glc~1~Man~9~GlcNAc; *2*, Man~9~GlcNAc; *3*, Man~8~GlcNAc; *4*, galactose; *5*, glucose; and *6*, mannose.](JCB9806006.f5){#F5}

![The unfolded protein response and underglycosylation of glycoproteins in *S. pombe* mutant cells. (*A*) Wild-type, *alg6*, *gpt1/alg6*, and *gls2/alg6* cells were grown in YE medium at 28°C, mRNAs were extracted and submitted to Northern blotting. A fragment of BiP-encoding DNA was used as probe. (*B*) Wild-type, *gls2*, and *alg6* mutant cells were incubated for 5 min with \[^35^S\]methionine and \[^35^S\]cysteine, and lysed in the presence of iodoacetamide. Material immunoprecipitated by antiserum to *S*. *pombe* calnexin was run on SDS-PAGE under reducing conditions and submitted to autoradiography.](JCB9806006.f6){#F6}

![Growth of wild-type and mutant cells at 28°C. Minimal medium plus adenine was used. The medium was supplemented with leucine and uracil (wild type) or with leucine (*gpt1*, *alg6*, and *gpt1/alg6*). Sp95 or Sp61 wild-type cells yielded similar growth curves.](JCB9806006.f7){#F7}

![Morphology of wild-type and mutant strains. (*A*) Wild type; (*B*) *alg6*; (*C*) *gpt1*; and (*D*) *gpt1/alg6*. Cells were grown at 28°C in minimal medium supplemented as in Fig. [7](#F7){ref-type="fig"}. Bar, 10 μm.](JCB9806006.f8){#F8}

![Growth of wild-type and mutant strains at 28°C and 37°C. Cells from indicated strains were plated in minimal medium supplemented as indicated in Fig. [7](#F7){ref-type="fig"}. Absorbance of initial inocula (3 μl) was in all cases 0.3. Following inocula correspond to one-tenth serial dilutions. All strains were incubated for 5 d except for *gls2/alg6* and *gpt1/alg6* that were incubated for 7 and 10 d, respectively.](JCB9806006.f9){#F9}

![Rescue of wild-type phenotype in mutant strains. *gpt1/alg6* cells were grown at 28°C in minimal medium supplemented as in Fig. [7](#F7){ref-type="fig"}. (*A*) 1 M sorbitol was added to the medium; (*B*) cells transformed with pREP1- *gpt1* ^+^; (*C*) cells transformed with pREP1; and (*D*) cells transformed with pREP1-*gpt1^YD-AA^*. Bar, 10 μm.](JCB9806006.f10){#F10}

###### 

Activity of Wild Type and Mutant GT Expressed in gpt1/alg6 Cells

  Addition             pREP1-*gpt1* ^+^      pREP1-*gpt1^YD-AA^*      pREP1
  ----------------- -- ------------------ -- --------------------- -- -------
  \-\-\-\-\-\-\--      13,840                 240                     330
  Thyroglobulin        98,550                1,080                    900

Values expressed are cpm/mg of microsomal protein precipitated by 10% trichloroacetic acid.  

![Morphology of wild-type and mutant strains. (*A*) Wild-type and (*B*) *gls2/alg6* cells were grown at 28°C in minimal medium supplemented with adenine, uracil and leucine (wild type) and adenine and leucine (*gls2/alg6*). Bar, 10 μm.](JCB9806006.f11){#F11}

[^1]: Address correspondence to A.J. Parodi, Instituto de Investigaciones Bioquímicas Fundación Campomar, Antonio Machado 151, 1405 Buenos Aires, Argentina. Tel.: (54-1) 863-4011. Fax: (54-1) 865-2246. E-mail: <aparodi@iris.iib.uba.ar>
